You are using an unsupported browser. This web site is designed for the current versions of Microsoft Edge, Google Chrome, Mozilla Firefox, or Safari.
The Office of the Federal Register publishes documents on behalf of Federal agencies but does not have any authority over their programs. We recommend you directly contact the agency associated with the content in question.
If you have comments or suggestions on how to improve the www.ecfr.gov website or have questions about using www.ecfr.gov, please choose the 'Website Feedback' button below.
If you would like to comment on the current content, please use the 'Content Feedback' button below for instructions on contacting the issuing agency
Enhanced content is provided to the user to provide additional context.
This content is from the eCFR and is authoritative but unofficial.
Navigate by entering citations or phrases (eg: 1 CFR 1.1 49 CFR 172.101 Organization and Purpose 1/1.1 Regulation Y FAR).
Choosing an item from citations and headings will bring you directly to the content. Choosing an item from full text search results will bring you to those results. Pressing enter in the search box will also bring you to search results.
Background and more details are available in the Search & Navigation guide.
The in-page Table of Contents is available only when multiple sections are being viewed.
Use the navigation links in the gray bar above to view the table of contents that this content belongs to.
48 FR 53047, Nov. 23, 1983, unless otherwise noted.
This content is from the eCFR and may include recent changes applied to the CFR. The official, published CFR, is updated annually and available below under "Published Edition". You can learn more about the process here.
Subscribe to: 21 CFR 890.5870
View the most recent official publication:
These links go to the official, published CFR, which is updated annually. As a result, it may not include the most recent changes applied to the CFR. Learn more.
Information and documentation can be found in our developer resources.
The Code of Federal Regulations (CFR) is the official legal print publication containing the codification of the general and permanent rules published in the Federal Register by the departments and agencies of the Federal Government. The Electronic Code of Federal Regulations (eCFR) is a continuously updated online version of the CFR. It is not an official legal edition of the CFR.
Learn more about the eCFR, its status, and the editorial process.
Nomenclature changes to part 890 appear at 73 FR 35341, June 23, 2008.
(a) Identification. A non-invasive bone growth stimulator is a prescription device that provides stimulation through electrical, magnetic, or ultrasonic fields. The device is intended to be used externally to promote osteogenesis as an adjunct to primary treatments for fracture fixation and spinal fusion or as a treatment for established nonunions or failed fusions.
(b) Classification. Class II (special controls). The special controls for this device are:
(1) Clinical data must demonstrate that the device performs as intended under anticipated conditions of use. Imaging data must demonstrate fusion at the treatment site.
(2) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. Critical performance and safety characteristics of the device, considering the operational modality of the device, must be verified and validated to ensure:
(i) Intended design outputs are delivered to the patient;
(ii) Thermal safety and thermal reliability;
(iii) Signal characteristics are within safe physiologic limits; and
(iv) Device reliability is consistent with the expected use-life.
(3) Patient-contacting components of the device must be demonstrated to be biocompatible.
(4) Performance data must demonstrate the electrical safety and electromagnetic compatibility of the device.
(5) Appropriate software verification, validation, and hazard analysis must be performed.
(6) Labeling comprehension testing must demonstrate the patient can correctly use the device based solely on reading the instructions for use.
(7) Labeling for the device must include the following:
(i) Warning against use on compromised skin or when there are known skin sensitivities;
(ii) Appropriate warnings for patients with implanted medical devices;
(iii) A detailed summary of the supporting clinical data, which includes the clinical outcomes associated with the use of the device, and a summary of adverse events and complications that occurred with the device;
(iv) A clear description of the device;
(v) Instructions on appropriate usage, duration, and frequency of use;
(vi) Instructions for maintenance and safe disposal;
(vii) Validated instructions for appropriate cleaning of any reusable components;
(viii) Specific warnings regarding user burns, electrical shock, and skin irritation; and
(ix) The risks and benefits associated with use of the device when used as intended.
[91 FR 20362, Apr. 16, 2026]